Piper Sandler upgraded shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) from a neutral rating to an overweight rating in a research note released on Wednesday, The Fly reports. A number of other brokerages have also issued reports on AKBA. StockNews.com lowered Akebia Therapeutics from a buy rating to a hold rating in a research […]
Akebia Therapeutics (NASDAQ:AKBA – Get Rating) was upgraded by equities research analysts at Piper Sandler from a “neutral” rating to an “overweight” rating in a research report issued to clients and investors on Wednesday, The Fly reports. Other analysts also recently issued reports about the company. StockNews.com downgraded Akebia Therapeutics from a “buy” rating to […]
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) was the recipient of a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 4,070,000 shares, a decline of 9.6% from the April 30th total of 4,500,000 shares. Based on an average daily volume of 1,720,000 shares, the […]
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) was the target of a significant drop in short interest in the month of May. As of May 15th, there was short interest totalling 4,070,000 shares, a drop of 9.6% from the April 30th total of 4,500,000 shares. Based on an average daily trading volume, of 1,720,000 shares, […]
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) SVP Nicole R. Hadas sold 63,186 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $1.22, for a total value of $77,086.92. Following the completion of the sale, the senior vice president now owns […]